Letybo

Botulinum toxin type A, the active ingredient in Letybo, is a neuromuscular blocker presented as a sterile injectable solution for intramuscular use. It provides temporary muscle relaxation in adult patients with conditions such as cervical dystonia, spasticity, blepharospasm, and chronic migraine.

GNH USA supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution, including cold‑chain logistics where required.

Letybo (botulinum toxin type A) is used to modulate excessive neuromuscular activity in several movement‑disorder and autonomic conditions. - Cervical dystonia: reduces abnormal neck muscle contractions and improves head posture. - Blepharospasm: relaxes overactive eyelid muscles to decrease involuntary blinking. - Upper limb spasticity: decreases muscle tone in the arm to improve functional movement. - Chronic migraine prophylaxis: lowers frequency of migraine attacks when administered per protocol. - Axillary hyperhidrosis: diminishes excessive sweating by blocking sympathetic nerve signals.

Adverse reactions to Letybo are generally related to the pharmacologic action of botulinum toxin and the injection procedure.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Bruising: localized discoloration due to minor bleeding. - Headache: transient headache occurring after treatment. - Flu-like symptoms: low-grade fever, fatigue or muscle aches.

Serious or Rare Side Effects: - Dysphagia: difficulty swallowing that may require medical attention. - Respiratory compromise: reduced breathing capacity due to spread of toxin. - Botulism-like syndrome: generalized muscle weakness resembling systemic botulism. - Allergic reaction: rash, itching, swelling or anaphylaxis.

Before using Letybo, consider the following precautions: - Pregnancy: avoid use unless benefits outweigh potential risks; limited data available. - Breastfeeding: consider risk‑benefit ratio; limited information on excretion in milk. - Neuromuscular disorders: assess patients with myasthenia gravis or Lambert‑Eaton syndrome before treatment. - Concomitant medications: avoid aminoglycoside antibiotics or other neuromuscular blocking agents when possible. - Contraindications: known hypersensitivity to botulinum toxin or human serum albumin. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Letybo may interact with other medicines; review the following categories.

Major Interactions (Avoid): - Aminoglycoside antibiotics: may potentiate neuromuscular blockade. - General anesthetics (e.g., succinylcholine): increased risk of prolonged paralysis. - Other botulinum toxin products: cumulative effect may enhance toxicity.

Moderate Interactions (Monitor Closely): - Muscle relaxants (e.g., baclofen): may augment muscle‑weakening effect. - Anticholinesterase agents (e.g., pyridostigmine): may reduce efficacy of toxin. - Vaccines (live attenuated): monitor immune response after administration.